Cardiac autonomic neuropathy (CAN) is a serious complication of diabetes. In this touchENDOCRINOLOGY interview, Dr Christian Hansen (Steno Diabetes Center Copenhagen, Birkerød, Denmark) discusses the clinical manifestations of CAN, its diagnosis and what medical devices are available for the detection of CAN.
The abstract entitled: ‘Cardiac Autonomic Neuropathy Sensors for Diabetes‘ was presented at the 22nd Annual Diabetes Technology Meeting, 03-05 Nov, 2022.
- What are the clinical manifestations of cardiac autonomic neuropathy (CAN) in diabetes? (0:17)
- How is CAN diagnosed? (0:45)
- What medical devices are available for the detection of CAN? (1:50)
Disclosures: Christian Hansen has nothing to disclose in relation to this video interview.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of DTM 2022
Share this Video
Related Videos In Diabetes
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!